Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM BMC Endocrine Disorders Pub Date : 2024-10-30 DOI:10.1186/s12902-024-01759-2

Qimou Chen, Liehua Liu, Weijian Ke, Xuhui Li, Haipeng Xiao, Yanbing Li

{"title":"Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.","authors":"Qimou Chen, Liehua Liu, Weijian Ke, Xuhui Li, Haipeng Xiao, Yanbing Li","doi":"10.1186/s12902-024-01759-2","DOIUrl":null,"url":null,"abstract":"Background and aims: In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.Methods: PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).Results: 49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).Conclusion: This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.Prospero registration number: CRD42024521252.","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523792/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Endocrine Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12902-024-01759-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.

Methods: PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).

Results: 49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).

Conclusion: This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.

Prospero registration number: CRD42024521252.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高级糖化终产物可溶性受体与糖尿病之间的关系：系统回顾和荟萃分析。

背景和目的：在 1 型糖尿病（T1DM）和 2 型糖尿病（T2DM）患者中，关于高级糖化终产物可溶性受体（sRAGE）的水平是否会发生显著变化，以往的研究结果并不一致。本荟萃分析旨在系统评估 T1DM 和 T2DM 患者体内 sRAGE 水平的变化：方法：系统检索了从开始到 2024 年 4 月的 PubMed、Embase 和 Web of Science。我们以非糖尿病健康人为对照组，纳入了报道 T1DM 或 T2DM 患者 sRAGE 水平的研究。采用随机效应模型对效应指标（均值和标度）进行荟萃分析：共有 32 项研究的 49 个数据集符合纳入标准，涉及 4948 名受试者。随机效应模型荟萃分析显示，T1DM 受试者（SMD 0.45，CI：0.16-0.73，P = 0.002）和有并发症的 T2DM 受试者（SMD 1.59，CI：0.77-2.41，P = 0.0001）的 sRAGE 水平显著高于对照组。在无并发症的 T2DM 受试者中，sRAGE 水平未观察到有统计学意义的变化（SMD 0.01，CI：-0.61-0.64，P = 0.97）。新诊断的 T2DM 患者的 sRAGE 水平下降（SMD-0.40，CI：-0.71--0.09，P = 0.01）：这项荟萃分析表明，T1DM 患者和有并发症的 T2DM 患者的 sRAGE 水平升高，而新诊断的 T2DM 患者的 sRAGE 水平降低。在无并发症的 T2DM 患者中未观察到明显差异。显然，T1DM 或 T2DM 患者体内 sRAGE 水平的变化并不一致，而是取决于疾病的不同类型和阶段：CRD42024521252。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Endocrine Disorders ENDOCRINOLOGY & METABOLISM-

CiteScore

4.40

自引率

0.00%

发文量

280

审稿时长

>12 weeks

期刊介绍： BMC Endocrine Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of endocrine disorders, as well as related molecular genetics, pathophysiology, and epidemiology.